Pacira price target lowered to $25 from $27 at Barclays

Barclays lowered the firm’s price target on Pacira (PCRX) to $25 from $27 and keeps an Equal Weight rating on the shares. The firm left the company’s Q4 report “encouraged” by its efforts to drive core revenue acceleration while investing in the pipeline. Pacira’s pipeline updates are back half of the year weighted, which could limit near-term positive momentum in the shares, the analyst tells investors in a research note.